Voya Investment Management LLC Has $219.39 Million Stake in Danaher Corporation $DHR

Voya Investment Management LLC lowered its position in shares of Danaher Corporation (NYSE:DHR) by 28.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,107,994 shares of the conglomerate’s stock after selling 448,706 shares during the period. Voya Investment Management LLC owned about 0.15% of Danaher worth $219,390,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. WFA of San Diego LLC acquired a new position in shares of Danaher in the second quarter valued at approximately $26,000. Howard Hughes Medical Institute bought a new stake in Danaher during the 2nd quarter worth approximately $27,000. Red Tortoise LLC increased its position in Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after acquiring an additional 98 shares during the period. Heartwood Wealth Advisors LLC bought a new position in shares of Danaher during the third quarter valued at $37,000. Finally, Ramirez Asset Management Inc. bought a new stake in shares of Danaher in the second quarter worth $40,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Up 0.8%

NYSE DHR opened at $224.43 on Friday. The stock has a market capitalization of $158.53 billion, a P/E ratio of 46.28, a P/E/G ratio of 4.32 and a beta of 0.89. The business has a 50 day simple moving average of $219.93 and a 200 day simple moving average of $206.66. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.71 earnings per share. Research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Teri List sold 3,298 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares in the company, valued at approximately $4,702,593. The trade was a 13.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 30,248 shares of company stock valued at $6,609,663. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Morgan Stanley assumed coverage on Danaher in a research report on Monday, December 1st. They set an “overweight” rating and a $270.00 target price for the company. Royal Bank Of Canada set a $241.00 price target on Danaher in a research note on Tuesday, September 2nd. Evercore ISI lifted their price objective on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Finally, Cowen restated a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Twenty-one analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $248.25.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.